GLP-1 SM

GLP-1 SM is a synthetic 31-residue peptide whose sequence corresponds to a chemically modified form of glucagon-like peptide-1, the incretin peptide derived from the proglucagon precursor and released from intestinal enteroendocrine L cells. The catalogue classes it as a synthetic GLP-1 receptor agonist peptide analogue: a laboratory-assembled molecule built on the GLP-1 backbone and altered at selected positions so that it differs from the native peptide in enzymatic stability assays. Analogues in this class are commonly prepared by solid-phase synthesis and carry a side-chain acylation, a general peptide-chemistry strategy used to promote reversible albumin association and to raise resistance to proteolysis in in-vitro assays.

The identifier recorded in the catalogue entry is the molecular formula, C187H291N45O59. A CAS registry number is not catalogued here and a molecular weight is not catalogued here, so neither value is stated. The full residue sequence and the positions of the modifications are likewise not recorded, and no sequence is asserted on this page. The material is listed under cell biology, is supplied lyophilized in a 10 mg vial, and carries no alternative catalogue synonyms.

Purity and identity are established by third-party HPLC and mass spectrometry, with a certificate of analysis for each lot. GLP-1 SM is supplied strictly for laboratory research and is not for human or veterinary use, nor for consumption, administration, diagnostic use or therapeutic use.